NCT00527943View on ClinicalTrials.gov

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

PHASE3TerminatedINTERVENTIONAL
Enrollment

12,944

Participants

Timeline

Start Date

December 1, 2007

Primary Completion Date

July 1, 2011

Study Completion Date

July 1, 2011

Conditions
AtherosclerosisMyocardial IschemiaMyocardial Infarction
Interventions
DRUG

Vorapaxar

oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year

DRUG

Placebo

oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year

Sponsors
All Listed Sponsors
collaborator

Duke Clinical Research Institute

OTHER

lead

Merck Sharp & Dohme LLC

INDUSTRY